Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Service

Funding, debt advisory & ECM

Parties

“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Talk to the deal team

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination

Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more

Agar Scientific has been acquired by Calibre Scientific

Private Equity | Healthcare

Agar Scientific has been acquired by Calibre Scientific

Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.

Learn more

Frenkel Topping has completed the placing of new shares

Financial Services

Frenkel Topping has completed the placing of new shares

Frenkel Topping has raised funds to continue consolidating the highly fragmented professional services marketplace in this niche sector.

Learn more